Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10908717 | Leukemia Research | 2015 | 7 Pages |
Abstract
The anti-tumor activity of AZD1480, a potent, selective inhibitor of Janus-associated kinases 1 and 2, was demonstrated in preclinical models of myeloproliferative neoplasms. In a phase I clinical study, 35 patients with myelofibrosis received 2.5-70Â mg AZD1480 orally once daily (QD) or 10 or 15Â mg twice daily (BID) continuously during repeated 28-day cycles. Two patients experienced dose-limiting toxicities: one patient in the 2.5Â mg QD cohort had a grade 3 lung infiltration/acute pneumonia, and one patient receiving 50Â mg QD had grade 3 presyncope. Dosing was stopped at 70Â mg QD after the first patient experienced an adverse neurological event (AE) and evidence of low-grade neurological toxicity in patients on lower doses after the initial month of therapy became apparent. The most common AZD1480-related AEs were dizziness and anemia. AZD1480 was absorbed quickly and eliminated from the plasma rapidly, with a mean terminal half-life of 2.45-8.06Â h; accumulation was not observed after repeated daily dosing for 28 days. Four patients showed evidence of clinical improvement based on IWG-MRT 2006 criteria. AZD1480 was relatively well tolerated, however, low-grade, reversible neurological toxicity was therapy limiting and led to study termination.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Srdan Verstovsek, Ronald Hoffman, John Mascarenhas, Jean-Charles Soria, Ratislav Bahleda, Patricia McCoon, Weifeng Tang, Jorge Cortes, Hagop Kantarjian, Vincent Ribrag,